Ms. Erickson has served as Savara’s Chief Business Officer since August 2023 and is responsible for the Investor Relations, Corporate Affairs, Project Management, Advocacy Relations & Patient Engagement, and Medical Affairs teams and leads corporate strategy projects. Since joining the company in October 2018, she’s held roles of increasing responsibility, including SVP of Global Business Operations, Chief of Staff, and Head of Investor Relations and Corporate Communications. Further, Ms. Erickson led the Clinical Operations Team for the IMPALA-2 trial (from study start-up through the double-blind period) and was also Interim Head of Quality Assurance. Prior to Savara, she held leadership roles within corporate, consulting, and agency settings at various companies, including Mirati Therapeutics, Halozyme, Pfizer, and Ogilvy.